Triple

T5932617
Position Surface form Disambiguated ID Type / Status
Subject ICH M4 Common Technical Document E131971 entity
Predicate adoptedBy P1034 FINISHED
Object Swissmedic
Swissmedic is the Swiss agency responsible for the authorization and supervision of therapeutic products, including medicines and medical devices, in Switzerland.
E555161 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Swissmedic | Statement: [ICH M4 Common Technical Document, adoptedBy, Swissmedic]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Swissmedic
Context triple: [ICH M4 Common Technical Document, adoptedBy, Swissmedic]
  • A. Federal Institute for Drugs and Medical Devices
    The Federal Institute for Drugs and Medical Devices is Germany’s central regulatory authority responsible for the authorization, safety monitoring, and risk assessment of pharmaceuticals and medical devices.
  • B. European Medicines Agency
    The European Medicines Agency is the European Union’s regulatory authority responsible for the scientific evaluation, supervision, and safety monitoring of medicines for human and veterinary use.
  • C. European medicines regulatory authorities
    European medicines regulatory authorities are national and regional agencies in Europe responsible for evaluating, authorizing, and monitoring the safety, quality, and efficacy of medicinal products.
  • D. Committee for Proprietary Medicinal Products
    The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
  • E. Swiss Academy of Medical Sciences
    The Swiss Academy of Medical Sciences is a leading Swiss institution that promotes excellence, ethics, and innovation in medical research and healthcare policy.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Swissmedic
Triple: [ICH M4 Common Technical Document, adoptedBy, Swissmedic]
Generated description
Swissmedic is the Swiss agency responsible for the authorization and supervision of therapeutic products, including medicines and medical devices, in Switzerland.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: Swissmedic
Target entity description: Swissmedic is the Swiss agency responsible for the authorization and supervision of therapeutic products, including medicines and medical devices, in Switzerland.
  • A. Federal Institute for Drugs and Medical Devices
    The Federal Institute for Drugs and Medical Devices is Germany’s central regulatory authority responsible for the authorization, safety monitoring, and risk assessment of pharmaceuticals and medical devices.
  • B. European Medicines Agency
    The European Medicines Agency is the European Union’s regulatory authority responsible for the scientific evaluation, supervision, and safety monitoring of medicines for human and veterinary use.
  • C. European medicines regulatory authorities
    European medicines regulatory authorities are national and regional agencies in Europe responsible for evaluating, authorizing, and monitoring the safety, quality, and efficacy of medicinal products.
  • D. Committee for Proprietary Medicinal Products
    The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
  • E. Swiss Academy of Medical Sciences
    The Swiss Academy of Medical Sciences is a leading Swiss institution that promotes excellence, ethics, and innovation in medical research and healthcare policy.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69c0085b75e88190a632f9691f9da48b completed March 22, 2026, 3:18 p.m.
NER Named-entity recognition batch_69c0389df18c81909027a9db7596f0c1 completed March 22, 2026, 6:44 p.m.
NED1 Entity disambiguation (via context triple) batch_69c0c064d2a4819096085668182cfde1 completed March 23, 2026, 4:24 a.m.
NEDg Description generation batch_69c0c109b3288190928dc4539a2872c2 completed March 23, 2026, 4:26 a.m.
NED2 Entity disambiguation (via description) batch_69c0c1f6fe60819080a00976740b6a9c completed March 23, 2026, 4:30 a.m.
Created at: March 22, 2026, 4 p.m.